Correction: Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors - Top-Institutions - MDSpire

Correction: Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors

  • By

  • Darren Hargrave

  • Lynley V. Marshall

  • Nicolas André

  • Julie Krystal

  • Brian H. Ladle

  • Karen A. Robbins

  • Stephan Hois

  • Jon Armstrong

  • Sarah Donegan

  • June 9, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Cincinnati Children’s Hospital Medical Center
    Cincinnati Children’s Hospital Medical Center

    Cincinnati, Ohio

    Key Differentiators

    • Pediatric Oncology

  • #2

    Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
    Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

    Boston, Massachusetts

    Key Differentiators

    • Pediatric Oncology
    • Immuno-Oncology

  • #3

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

Original Source(s)

Correction: Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors

  • by Darren Hargrave, Lynley V. Marshall, Nicolas André, Julie Krystal, Brian H. Ladle, Karen A. Robbins, Stephan Hois, Jon Armstrong, Sarah Donegan

  • June 9, 2026

Related Content

First-line serplulimab plus chemotherapy versus chemotherapy alone in small-cell lung cancer patients with brain metastases: a multicenter, prospective cohort study

Challenges and emerging strategies for genome-wide evaluation of loss of imprinting in cancer

Baseline vs. on-treatment heart failure with preserved ejection fraction (HFpEF) in a real world cardio-oncology clinic: observational analysis of cancer therapy-related cardiovascular toxicity incidence and cancer treatment implications